Gastric and esophageal cancer: Post ASCO 2015

Abstract Immunologic tumor therapy was the leading theme of this year’s ASCO. In this context first results for check point inhibitors active in esophageal and gastric cancer were presented. Phase III trials involving c-met inhibitors however were not successful. First phase II results with regorafenib emphasize a potential role for TKI’s in gastric cancer.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research